Open-label Study of CS-1008 for Subjects With Untreated and Unresectable Pancreatic Cancer
Status:
Completed
Trial end date:
2010-08-20
Target enrollment:
Participant gender:
Summary
Phase 2 study to determine the efficacy and safety of CS-1008 when given with gemcitabine to
subjects with previously untreated and unresectable (unable to be surgically removed) or
metastatic (spread to other areas beyond the pancreas) pancreatic cancer.